These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 25794658)

  • 1. Seasonal risk factors for asthma exacerbations among inner-city children.
    Teach SJ; Gergen PJ; Szefler SJ; Mitchell HE; Calatroni A; Wildfire J; Bloomberg GR; Kercsmar CM; Liu AH; Makhija MM; Matsui E; Morgan W; O'Connor G; Busse WW
    J Allergy Clin Immunol; 2015 Jun; 135(6):1465-73.e5. PubMed ID: 25794658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma.
    Sheehan WJ; Krouse RZ; Calatroni A; Gergen PJ; Gern JE; Gill MA; Gruchalla RS; Khurana Hershey GK; Kattan M; Kercsmar CM; Lamm CI; Little FF; Makhija MM; Searing DA; Zoratti E; Busse WW; Teach SJ;
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3021-3028.e2. PubMed ID: 32376491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exhaled nitric oxide levels to guide treatment for children with asthma.
    Petsky HL; Kew KM; Chang AB
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD011439. PubMed ID: 27825189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence.
    Gruchalla RS; Sampson HA; Matsui E; David G; Gergen PJ; Calatroni A; Brown M; Liu AH; Bloomberg GR; Chmiel JF; Kumar R; Lamm C; Smartt E; Sorkness CA; Steinbach SF; Stone KD; Szefler SJ; Busse WW
    J Allergy Clin Immunol; 2009 Aug; 124(2):213-21, 221.e1. PubMed ID: 19615730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.
    Teach SJ; Gill MA; Togias A; Sorkness CA; Arbes SJ; Calatroni A; Wildfire JJ; Gergen PJ; Cohen RT; Pongracic JA; Kercsmar CM; Khurana Hershey GK; Gruchalla RS; Liu AH; Zoratti EM; Kattan M; Grindle KA; Gern JE; Busse WW; Szefler SJ
    J Allergy Clin Immunol; 2015 Dec; 136(6):1476-1485. PubMed ID: 26518090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L; Newbold P; Wu Y; Trudo F
    Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for Asthma Exacerbation and Treatment Failure in Adults and Adolescents with Well-controlled Asthma during Continuation and Step-Down Therapy.
    DiMango E; Rogers L; Reibman J; Gerald LB; Brown M; Sugar EA; Henderson R; Holbrook JT
    Ann Am Thorac Soc; 2018 Aug; 15(8):955-961. PubMed ID: 29863899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractional exhaled nitric oxide change in pediatric patients after emergency department care of asthma exacerbations.
    Karlin E; Gebretsadik T; Peebles RS; Hartert TV; Langley EW; Arnold DH
    Ann Allergy Asthma Immunol; 2015 Feb; 114(2):149-51. PubMed ID: 25492099
    [No Abstract]   [Full Text] [Related]  

  • 11. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults.
    Petsky HL; Li A; Chang AB
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD005603. PubMed ID: 28837221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In moderate-to-severe asthma patients monitoring exhaled nitric oxide during exacerbation is not a good predictor of spirometric response to oral corticosteroid.
    Gelb AF; Moridzadeh R; Singh DH; Fraser C; George SC
    J Allergy Clin Immunol; 2012 Jun; 129(6):1491-8. PubMed ID: 22560478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents.
    Pongracic JA; Krouse RZ; Babineau DC; Zoratti EM; Cohen RT; Wood RA; Khurana Hershey GK; Kercsmar CM; Gruchalla RS; Kattan M; Teach SJ; Johnson CC; Bacharier LB; Gern JE; Sigelman SM; Gergen PJ; Togias A; Visness CM; Busse WW; Liu AH
    J Allergy Clin Immunol; 2016 Oct; 138(4):1030-1041. PubMed ID: 27720017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we predict fall asthma exacerbations? Validation of the seasonal asthma exacerbation index.
    Hoch HE; Calatroni A; West JB; Liu AH; Gergen PJ; Gruchalla RS; Khurana Hershey GK; Kercsmar CM; Kim H; Lamm CI; Makhija MM; Mitchell HE; Teach SJ; Wildfire JJ; Busse WW; Szefler SJ
    J Allergy Clin Immunol; 2017 Oct; 140(4):1130-1137.e5. PubMed ID: 28238748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
    Trevor J; Lugogo N; Carr W; Moore WC; Soong W; Panettieri RA; Desai P; Trudo F; Ambrose CS
    Ann Allergy Asthma Immunol; 2021 Nov; 127(5):579-587.e1. PubMed ID: 34273485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations.
    Bateman ED; Buhl R; O'Byrne PM; Humbert M; Reddel HK; Sears MR; Jenkins C; Harrison TW; Quirce S; Peterson S; Eriksson G
    J Allergy Clin Immunol; 2015 Jun; 135(6):1457-64.e4. PubMed ID: 25258144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy: a randomised trial (RAACENO).
    Turner S; Cotton SC; Emele CD; Thomas R; Fielding S; Gaillard EA; de Jongste JC; Morgan H; Neilson AR; Norrie J; Pijnenburg M; Price D; Thomas M
    Trials; 2019 Oct; 20(1):573. PubMed ID: 31585544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care.
    Honkoop PJ; Loijmans RJ; Termeer EH; Snoeck-Stroband JB; van den Hout WB; Bakker MJ; Assendelft WJ; ter Riet G; Sterk PJ; Schermer TR; Sont JK;
    J Allergy Clin Immunol; 2015 Mar; 135(3):682-8.e11. PubMed ID: 25174865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial.
    Szefler SJ; Mitchell H; Sorkness CA; Gergen PJ; O'Connor GT; Morgan WJ; Kattan M; Pongracic JA; Teach SJ; Bloomberg GR; Eggleston PA; Gruchalla RS; Kercsmar CM; Liu AH; Wildfire JJ; Curry MD; Busse WW
    Lancet; 2008 Sep; 372(9643):1065-72. PubMed ID: 18805335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can exhaled nitric oxide fraction predict adherence to inhaled corticosteroids in atopic and nonatopic children with asthma?
    Klok T; Brand PLP
    J Allergy Clin Immunol Pract; 2017; 5(2):521-522. PubMed ID: 27888027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.